August 6, 2024 01:21 PM EDTUpdated August 7, 08:57 AM
Pharma
Law

No­vo Nordisk goes af­ter more com­pounders, ex­pand­ing GLP-1 law­suit cam­paign

Nicole DeFeudis

Editor

No­vo Nordisk is turn­ing up the heat on com­pound­ing phar­ma­cies mak­ing ver­sions of its block­buster.

Late last week, the com­pa­ny filed 11 new law­suits against …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

A service from the Financial Times